Literature DB >> 26045650

Dyslipidemia: blockbuster therapies are on the horizon.

Rinki Patel, Kunj Gohil.   

Abstract

Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales.

Entities:  

Year:  2015        PMID： 26045650      PMCID： PMC4450671     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  The burden and management of dyslipidemia: practical issues.

Authors:  Alyssa B Schultz; Chin-Yu Chen; Wayne N Burton; Dee W Edington
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

Review 2.  Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.

Authors:  Kiran Musunuru
Journal:  Lipids       Date:  2010-06-04       Impact factor: 1.880
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.